The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines repair, replace, and regenerate tissues and organs affected due to injury, disease, or natural ageing process. These medicines help restore the functionality of cells & tissues and are applicable in numerous degenerative disorders such as dermatology, neurodegenerative diseases, cardiovascular, and orthopedic applications. Researchers focus on developing technologies based on biologics, genes, somatic as well as stem cells. Stem cells are capable of proliferation and differentiation and hence, are critical in this field.
The major factors that boost the market growth include technological advancements in tissue and organ regeneration, increase in prevalence of chronic diseases and trauma emergencies, prominent potential of nanotechnology, and emergence of stem cell technology. In addition, rise in degenerative diseases and shortage of organs for transplantation are expected to fuel the growth of the market. Moreover, utilization of nanomaterials in wound care, drug delivery, and immunomodulation has opened numerous growth avenues for the regenerative medicines market. However, stringent regulatory barriers and high cost of the treatment are likely to hinder the market growth.
The global regenerative medicine market is segmented based on product type, material, application, and geography. Based on product type, the market is classified into cell therapy, gene therapy, tissue engineering, and small molecule & biologic. Depending on material, it is categorized into synthetic material, biologically derived material, genetically engineered material, and pharmaceutical. Synthetic material is further divided into biodegradable synthetic polymer, scaffold, artificial vascular graft material, and hydrogel material. Biologically derived material is further bifurcated into collagen and xenogenic material. Genetically engineered material is further segmented into deoxyribonucleic acid, transfection vector, genetically manipulated cell, three-dimensional polymer technology, transgenic, fibroblast, neural stem cell, and gene-activated matrices. Pharmaceutical is further divided into small molecule and biologic. By application, it is categorized into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. Geographically, it is analyzed across four regions, i.e., North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS FOR STAKEHOLDERS
This report offers a detailed quantitative analysis of the market trends from 2016 to 2023 to identify the prevailing opportunities.
The market estimations provided in this report are based on a comprehensive analysis of the key developments in the industry.
An in-depth analysis based on geography facilitates the study of the regional market to assist in strategic business planning.
The development strategies adopted by the key manufacturers are enlisted in the report to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Product Type
Small Molecule & Biologic
Biodegradable Synthetic Polymer
Artificial Vascular Graft Material
Biologically Derived Material
Genetically Engineered Material
Deoxyribonucleic Acid Transfection Vectors
Genetically Manipulated Cell
Three-Dimensional Polymer Technology
Neural Stem Cell
Rest of Europe
Rest of Asia-Pacific
Rest of LAMEA
KEY PLAYERS PROFILED
Zimmer Biomet Holdings, Inc.
U.S. Stem Cell, Inc. (Bioheart, Inc.)
Organogenesis, Inc. (Advanced Biohealing)
Integra Lifesciences Holdings Corporation
Acelity Holdings, Inc.
Isto Biologics (Isto Biologics Medical Systems, Inc.)
The other players of the Regenerative Medicine market include (companies not profiled in the report):
Shimadzu Recursion Pharmaceuticals, Inc.
Baxter International, Inc.
General Electric (GE) Company
Koninklijke Philips N.V.
Bay Labs, Inc.